Over 88% Of Wegovy Trial Participants Achieve Normal Liver Fat Levels, Novo Reports

기사 요약

Novo Nordisk's Wegovy significantly reduced liver fat in adults with obesity in a recent post hoc analysis, potentially lowering MASH risk.